Skip to search formSkip to main contentSkip to account menu

eprosartan

Known as: Éprosartan, (e)-2-Butyl-1-(P-carboxybenzyl)-alpha-2-thenylimidazole-5-acrylic acid, 2-Thiophenepropanoic acid, alpha-((2-butyl-1-((4- carboxyphenyl)methyl)-lH-imidazol-5-yl)methylene)-, (E)- 
A competitive and reversible angiotensin II receptor antagonist with anti-hypertensive property. Eprosartan blocks the binding of angiotensin II to… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
The degradation of eprosartan was evaluated under ICH/WHO prescribed stress conditions. The drug degraded to only one product… 
2011
2011
An accurate, highly sensitive, precise and reproducible isocratic RP-HPLC method was developed and subsequent validated for the… 
2010
2010
A simple, precise, and accurate isocratic RP-HPLC method was developed and validated for determination of eprosartan in bulk drug… 
2008
2008
The influence of angiotensin II blocker in thrombocytes aggregative capacity in patients with arterial hypertension and metabolic… 
2008
2008
The influence of angiotensin II blocker in thrombocytes aggregative capacity in patients with arterial hypertension and metabolic… 
2006
2006
Antihypertensive drug eprosartan from the group of angiotensin II receptor blockers was studied from the position of its effect… 
2005
2005
The study examined a number of parameters of platelet function and activation in hypertensive patients compared with normotensive… 
Review
2002
Review
2002
Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the… 
2001
2001
Cytochromes P450 (P450, CYP) are a superfamily of enzymes that participate especially in the oxidative metabolism of various… 
1999
1999
Henriksen, Erik J., Stephan Jacob, Tyson R. Kinnick, Erik B. Youngblood, Melanie B. Schmit, and Guenther J. Dietze. ACE…